The Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.
Cancer is a serious medical condition marked by the presence of tumor cells present in the body. The formation of tumor cells take place when the normal cells grow at an abnormal rate. Moreover, these tumor cells also have the ability to spread to other parts of the body through blood and lymphatic system. In addition, cancer has different stages which are based on the growth pattern of tumor. Therefore, the treatment of cancer differs depending on the stage of cancer. Chemotherapy drugs are mostly employed in the treatment of early stage cancers and similarly targeted therapy and immunotherapy drugs are generally preferred in the treatment of late stage cancers.
Surge in research related to new drug discovery for cancer treatment, rise in incidence of cancer in Japan, and increase in healthcare expenditure boost the growth of Japan oncology drugs market. Moreover, rise in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, stringent approval process of oncology drugs in Japan hinders the growth of market.
The Japan oncology drugs market size is studied based on segments, drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
By Drug Class Type
By Indication
List of key players profiled in the report:
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Surge in research related to new drug discovery for cancer treatment, rise in incidence of cancer in Japan, and increase in healthcare expenditure boost the growth of Japan oncology drugs market. Moreover, rise in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, stringent approval process of oncology drugs in Japan hinders the growth of market.
The Japan oncology drugs market size is studied based on segments, drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Japan market
- A qualitative analysis based on innovative products facilitates strategic business planning.
Key Market Segments
By Drug Class Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
By Indication
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Lung Cancer
- Skin Cancer
- Ovarian Cancer
- Cervical Cancer
- Other Cancers
List of key players profiled in the report:
- Otsuka Holdings Co Ltd
- Johnson and Johnson
- Daiichi Sankyo Co Ltd
- AstraZeneca plc
- AbbVie Inc.
- Celgene Corporation
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Ltd
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Sanofi
- Amgen Inc.
- Bayer AG
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Oncology Drugs Market, By Drug Class Type
Chapter 5: Oncology Drugs Market, By Indication
Chapter 6: Company Profiles
Executive Summary
According to the report titled, 'Japan Oncology Drugs Market by Drug Class Type, and Indication: Opportunity Analysis and Industry Forecast, 2019-2026,' the Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.Cancerous cells are formed when the normal cells present in the body grow at an uncontrolled rate. This abnormal growth leads to the formation of a tumor which can spread to other localized tissues. Moreover, cancer has different stages based on the growth of tumor. Metastasis is the final stage of the disease, which is marked by the invasion of tumor in other parts of the body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.
Factors such as rise in incidence of cancer in Japan, increase in healthcare expenditure and surge in research related to new drug discovery for cancer treatment in the region are the major factors that boost the growth of Japan oncology drugs market. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. Moreover, surge in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of market
The Japan oncology drugs market is segmented on the basis of drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.
Depending on drug class type, the targeted therapy segment occupied the largest share of Japan oncology drugs market in 2018. This is attributed to lesser side effects of the targeted therapy drugs as compared to other treatment options. Targeted therapies have the ability to kill only malignant cells thereby exhibiting better treatment outcomes which fuel the growth of market. In addition, higher efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. Furthermore, immunotherapy segment is expected to show fastest growth during the forecast period. This is due to wide acceptance of immunotherapy drugs as an ideal treatment option for cancer. Immunotherapy drugs are ideal treatment options as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for market growth.
Based on indication, the prostate cancer segment occupied the largest share of market in 2018 owing to the presence of huge geriatric population. However, lung cancer segment is expected to show fastest growth during the forecast period attributed to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.
According to Onkar Sumant, Manager, Healthcare Analyst, “Surge in prevalence of cancer is anticipated to significantly drive the growth of the Japan oncology drugs market. Furthermore, rise in geriatric population, increase in healthcare expenditure, and upsurge in awareness related to early screening of cancer are the key factors that augment the market growth.”
Key Findings of the Japan Oncology Drugs Market:
Targeted therapy occupied approximately half share of the Japan oncology drugs market in 2018.
The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.
The gastrointestinal cancer segment accounted for two-fifth share of the market in 2018.
Lung cancer is anticipated to grow at the highest rate during the analysis period.
Companies Mentioned
- Otsuka Holdings Co Ltd
- Johnson Johnson
- Daiichi Sankyo Co Ltd
- AstraZeneca plc
- AbbVie Inc.
- Celgene Corporation
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
